Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870.
Identifieur interne : 000D92 ( PubMed/Curation ); précédent : 000D91; suivant : 000D93Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870.
Auteurs : Qi-Fei Zhong [République populaire de Chine] ; Rui Liu [République populaire de Chine] ; Gang Liu [République populaire de Chine]Source :
- Molecular diversity [ 1573-501X ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- pharmacocinétique : Amines.
- pharmacologie : Antiviraux.
- synthèse chimique : Amines, Antiviraux.
- Amines, Antiviraux, Hepacivirus, Humains, Lignée cellulaire, Quinoxalines, Relation structure-activité, Réplication virale, Structure moléculaire.
English descriptors
- KwdEn :
- Amines (chemical synthesis), Amines (chemistry), Amines (pharmacokinetics), Antiviral Agents (chemical synthesis), Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Cell Line, Hepacivirus (drug effects), Humans, Molecular Structure, Quinoxalines (chemistry), Structure-Activity Relationship, Virus Replication (drug effects).
- MESH :
- chemical , chemical synthesis : Amines, Antiviral Agents.
- chemical , chemistry : Amines, Antiviral Agents, Quinoxalines.
- chemical , pharmacokinetics : Amines.
- chemical , pharmacology : Antiviral Agents.
- drug effects : Hepacivirus, Virus Replication.
- Cell Line, Humans, Molecular Structure, Structure-Activity Relationship.
Abstract
Chronic hepatitis C virus infection represents a serious global public health problem, typically resulting in fibrosis, cirrhosis, and ultimately hepatocellular carcinoma. Based on our previous discovery of lead compound 2 (Liu et al. J Med Chem 54:5747-5768, 2011), 35 new quinoxalinone derivatives were explored in this study. Outline of the structure-activity relationships (SARs) revealed that compound BH6870 (36) showed high anti-HCV potency ([Formula: see text]) and a good cell safety index (SI [Formula: see text]). SARs analysis indicated that quinoxalin-2(1H)-one containing a 4-aryl-substituted thiazol-2-amine moiety was optimal for antiviral activity. Introducing a hydrogen-bond acceptor (such as ester or amide group) at the C-3 position of quinoxalin-2(1H)-one was beneficial for the antiviral potency, and especially, N,N-disubstituted amide was far superior to N-monosubstituted amide. Incorporation of more than one halogen (fluorine or chlorine atom) or a strong electron-withdrawing group on the benzene ring of the thiazole-phenyl moiety might reduce electron atmosphere density further and resulted in a dramatical loss of activity. The NH-group of the lactam moiety was clearly required for anti-HCV activity. Design and synthesis of quinoxalin-2(1H)-one derivatives as new non-nucleoside small-molecule HCV inhibitors. BH6870 (36), showing higher antiviral potency and a good cell safety index, was identified.
DOI: 10.1007/s11030-015-9610-6
PubMed: 26205408
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D92
Links to Exploration step
pubmed:26205408Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870.</title>
<author><name sortKey="Zhong, Qi Fei" sort="Zhong, Qi Fei" uniqKey="Zhong Q" first="Qi-Fei" last="Zhong">Qi-Fei Zhong</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Liu, Rui" sort="Liu, Rui" uniqKey="Liu R" first="Rui" last="Liu">Rui Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Liu, Gang" sort="Liu, Gang" uniqKey="Liu G" first="Gang" last="Liu">Gang Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050, People's Republic of China. gangliu27@gmail.com.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26205408</idno>
<idno type="pmid">26205408</idno>
<idno type="doi">10.1007/s11030-015-9610-6</idno>
<idno type="wicri:Area/PubMed/Corpus">000D92</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D92</idno>
<idno type="wicri:Area/PubMed/Curation">000D92</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D92</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870.</title>
<author><name sortKey="Zhong, Qi Fei" sort="Zhong, Qi Fei" uniqKey="Zhong Q" first="Qi-Fei" last="Zhong">Qi-Fei Zhong</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Liu, Rui" sort="Liu, Rui" uniqKey="Liu R" first="Rui" last="Liu">Rui Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Liu, Gang" sort="Liu, Gang" uniqKey="Liu G" first="Gang" last="Liu">Gang Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050, People's Republic of China. gangliu27@gmail.com.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Molecular diversity</title>
<idno type="eISSN">1573-501X</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amines (chemical synthesis)</term>
<term>Amines (chemistry)</term>
<term>Amines (pharmacokinetics)</term>
<term>Antiviral Agents (chemical synthesis)</term>
<term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Cell Line</term>
<term>Hepacivirus (drug effects)</term>
<term>Humans</term>
<term>Molecular Structure</term>
<term>Quinoxalines (chemistry)</term>
<term>Structure-Activity Relationship</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Amines ()</term>
<term>Amines (pharmacocinétique)</term>
<term>Amines (synthèse chimique)</term>
<term>Antiviraux ()</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (synthèse chimique)</term>
<term>Hepacivirus ()</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Quinoxalines ()</term>
<term>Relation structure-activité</term>
<term>Réplication virale ()</term>
<term>Structure moléculaire</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Amines</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Amines</term>
<term>Antiviral Agents</term>
<term>Quinoxalines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Amines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hepacivirus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Amines</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Amines</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Line</term>
<term>Humans</term>
<term>Molecular Structure</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Amines</term>
<term>Antiviraux</term>
<term>Hepacivirus</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Quinoxalines</term>
<term>Relation structure-activité</term>
<term>Réplication virale</term>
<term>Structure moléculaire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chronic hepatitis C virus infection represents a serious global public health problem, typically resulting in fibrosis, cirrhosis, and ultimately hepatocellular carcinoma. Based on our previous discovery of lead compound 2 (Liu et al. J Med Chem 54:5747-5768, 2011), 35 new quinoxalinone derivatives were explored in this study. Outline of the structure-activity relationships (SARs) revealed that compound BH6870 (36) showed high anti-HCV potency ([Formula: see text]) and a good cell safety index (SI [Formula: see text]). SARs analysis indicated that quinoxalin-2(1H)-one containing a 4-aryl-substituted thiazol-2-amine moiety was optimal for antiviral activity. Introducing a hydrogen-bond acceptor (such as ester or amide group) at the C-3 position of quinoxalin-2(1H)-one was beneficial for the antiviral potency, and especially, N,N-disubstituted amide was far superior to N-monosubstituted amide. Incorporation of more than one halogen (fluorine or chlorine atom) or a strong electron-withdrawing group on the benzene ring of the thiazole-phenyl moiety might reduce electron atmosphere density further and resulted in a dramatical loss of activity. The NH-group of the lactam moiety was clearly required for anti-HCV activity. Design and synthesis of quinoxalin-2(1H)-one derivatives as new non-nucleoside small-molecule HCV inhibitors. BH6870 (36), showing higher antiviral potency and a good cell safety index, was identified. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26205408</PMID>
<DateCompleted><Year>2016</Year>
<Month>04</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-501X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>19</Volume>
<Issue>4</Issue>
<PubDate><Year>2015</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Molecular diversity</Title>
<ISOAbbreviation>Mol. Divers.</ISOAbbreviation>
</Journal>
<ArticleTitle>Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870.</ArticleTitle>
<Pagination><MedlinePgn>829-53</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11030-015-9610-6</ELocationID>
<Abstract><AbstractText>Chronic hepatitis C virus infection represents a serious global public health problem, typically resulting in fibrosis, cirrhosis, and ultimately hepatocellular carcinoma. Based on our previous discovery of lead compound 2 (Liu et al. J Med Chem 54:5747-5768, 2011), 35 new quinoxalinone derivatives were explored in this study. Outline of the structure-activity relationships (SARs) revealed that compound BH6870 (36) showed high anti-HCV potency ([Formula: see text]) and a good cell safety index (SI [Formula: see text]). SARs analysis indicated that quinoxalin-2(1H)-one containing a 4-aryl-substituted thiazol-2-amine moiety was optimal for antiviral activity. Introducing a hydrogen-bond acceptor (such as ester or amide group) at the C-3 position of quinoxalin-2(1H)-one was beneficial for the antiviral potency, and especially, N,N-disubstituted amide was far superior to N-monosubstituted amide. Incorporation of more than one halogen (fluorine or chlorine atom) or a strong electron-withdrawing group on the benzene ring of the thiazole-phenyl moiety might reduce electron atmosphere density further and resulted in a dramatical loss of activity. The NH-group of the lactam moiety was clearly required for anti-HCV activity. Design and synthesis of quinoxalin-2(1H)-one derivatives as new non-nucleoside small-molecule HCV inhibitors. BH6870 (36), showing higher antiviral potency and a good cell safety index, was identified. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName>
<ForeName>Qi-Fei</ForeName>
<Initials>QF</Initials>
<AffiliationInfo><Affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Rui</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Gang</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2 Nanwei Rd., Xicheng Dist., Beijing, 100050, People's Republic of China. gangliu27@gmail.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Tsinghua-Peking Center for Life Sciences and Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Haidian Dist., Beijing, 100084, People's Republic of China. gangliu27@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Mol Divers</MedlineTA>
<NlmUniqueID>9516534</NlmUniqueID>
<ISSNLinking>1381-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000588">Amines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000588" MajorTopicYN="N">Amines</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral activity</Keyword>
<Keyword MajorTopicYN="N">Hepatitis C virus</Keyword>
<Keyword MajorTopicYN="N">Quinoxalinone</Keyword>
<Keyword MajorTopicYN="N">Structure–activity relationships</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>04</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>06</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>7</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>7</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>4</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26205408</ArticleId>
<ArticleId IdType="doi">10.1007/s11030-015-9610-6</ArticleId>
<ArticleId IdType="pii">10.1007/s11030-015-9610-6</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2009 Apr 30;360(18):1827-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19403902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Org Chem. 2004 Feb 6;69(3):977-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14750833</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2006 Mar;50(3):1013-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16495264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2014 Mar 13;57(5):1673-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24446688</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2010 May 5;2(30):30ra32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20445200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23856779</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gastroenterol. 2014 Jan;49(1):163-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24356811</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hepatology. 2009 Apr;49(4):1335-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19330875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2011 Aug 25;54(16):5747-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21761853</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hepatology. 2013 Dec;58(6):1918-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23907700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2010 Nov 15;202(10 ):1510-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20942646</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2012 Oct;56(10):5387-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22869577</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2014 Feb;146(2):430-41.e6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24184810</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>World J Gastroenterol. 2013 Dec 21;19(47):8940-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24379619</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gut. 2012 May;61 Suppl 1:i36-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22504918</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2007 Jun;5(6):453-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17487147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Rev. 2000 Apr;13(2):223-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10755999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2011 Nov 08;29(11):993-1003</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22068541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 Aug 15;369(7):630-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23944300</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2009 Jan 8;52(1):206-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19072694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Apr 30;360(18):1839-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19403903</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2012 Jul 20;429(1):57-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22543048</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2005 Sep;5(9):558-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16122679</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2013 Sep 1;443(2):278-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23763767</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1989 Apr 21;244(4902):359-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2523562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2010 Apr;86(1):79-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20417376</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Jan 19;366(3):216-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22256805</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2011 Mar 31;364(13):1207-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21449784</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gastroenterol. 2014 Jan;49(1):138-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24005956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Transl Med. 2013 Apr 11;2(1):9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23577631</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(6):e39163</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22720059</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Rev. 1996 Dec 19;96(8):3147-3176</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11848856</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2011 Mar 31;364(13):1195-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21449783</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2011 Jun 23;364(25):2417-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21696308</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2011 Jun 23;364(25):2405-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21696307</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Liver Int. 2012 Feb;32 Suppl 1:88-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22212578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2014 Mar 13;57(5):1845-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24159919</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Liver Int. 2014 Jan;34(1):78-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23944720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hepatology. 2012 Sep;56(3):884-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22473713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hepatology. 2012 Apr;55(4):1030-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22095398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2006 Mar;50(3):899-909</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16495249</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2010 Oct 14;53(19):7202-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20845908</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Med. 2012;63:373-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21942423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2011 Sep;55(9):4196-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21746939</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2013 Jul;59(1):11-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23439259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Biol Ther. 2011 Dec;11(12):1611-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21995412</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2011 Jul 11;29(7):553-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21747363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2002 Nov;1(11):867-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12415247</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Investig Drugs. 2010 Aug;19(8):963-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20629614</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 Jan 3;368(1):34-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23281974</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Stud Hematol Blood Transfus. 1998;(62):38-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9507803</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D92 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000D92 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:26205408 |texte= Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26205408" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |